Cargando…

Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial

BACKGROUND: Pruritus is a troublesome side effect of intrathecal opioids. Midazolam can reinforce GABA-mediated inhibition of the medullary dorsal horn neurons, and thus theoretically has potential to suppress opioid-induced pruritus. OBJECTIVES: This prospective double-blinded randomized trial aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Makarem, Jalil, Mireskandari, Seyed Mohammad, Jafarzadeh, Afshin, Rahbar Nikoukar, Laya, Aghaii, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696882/
https://www.ncbi.nlm.nih.gov/pubmed/29181332
http://dx.doi.org/10.5812/aapm.37535
_version_ 1783280528872439808
author Makarem, Jalil
Mireskandari, Seyed Mohammad
Jafarzadeh, Afshin
Rahbar Nikoukar, Laya
Aghaii, Sara
author_facet Makarem, Jalil
Mireskandari, Seyed Mohammad
Jafarzadeh, Afshin
Rahbar Nikoukar, Laya
Aghaii, Sara
author_sort Makarem, Jalil
collection PubMed
description BACKGROUND: Pruritus is a troublesome side effect of intrathecal opioids. Midazolam can reinforce GABA-mediated inhibition of the medullary dorsal horn neurons, and thus theoretically has potential to suppress opioid-induced pruritus. OBJECTIVES: This prospective double-blinded randomized trial aimed at comparing the effects of propofol, midazolam, and a combination of the two on the prevention of pruritus induced by intrathecal sufentanil. METHODS: Eighty-four patients undergoing spinal anesthesia with 3 mL hyperbaric bupivacaine 0.5% and 5 μg sufentanil (1 mL) were randomly allocated to one of the three study groups: Group 1, who were administered 20 mg intravenous (IV) propofol bolus, then 50 μg/kg/min IV infusion; Group 2, who were administered 0.03 mg/kg IV midazolam bolus, then 0.02 mg/kg/h IV infusion; and Group 3, who were administered 10 mg IV propofol and 0.015 mg/kg IV midazolam bolus, then 25 μg/kg/min propofol and 0.01 mg/kg/h midazolam IV infusion. The incidence rates and severity of pruritus were assessed intraoperatively and postoperatively for 24 hours. RESULTS: The Ramsay Sedation Score was highest for the propofol group throughout the duration of the anesthetic process. Overall, 17 patients in the propofol group (60.7%), eight patients in the midazolam group (28.6%), and nine patients in the propofol-midazolam group (32.1%) developed pruritus (P = 0.027). Intraoperative pruritus was observed in seven patients in the propofol group (25%), two patients in the midazolam group (7.1%), and five patients in the midazolam-propofol group (17.9%) (P = 0.196). Postoperative pruritus developed in 12 patients in the propofol group (42.9%), six patients in the midazolam group (21.4%), and four patients in the midazolam-propofol group (14.3%) (P = 0.041). There was no significant difference between the groups with respect to the severity of pruritus (P > 0.05). CONCLUSIONS: This study showed that in comparison with propofol, the administration of 0.03 mg/kg IV midazolam bolus followed by 0.02 mg/kg/h could be more effective in the prevention of intrathecal sufentanil-induced pruritus without increasing sedation and other side effects.
format Online
Article
Text
id pubmed-5696882
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-56968822017-11-27 Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial Makarem, Jalil Mireskandari, Seyed Mohammad Jafarzadeh, Afshin Rahbar Nikoukar, Laya Aghaii, Sara Anesth Pain Med Research Article BACKGROUND: Pruritus is a troublesome side effect of intrathecal opioids. Midazolam can reinforce GABA-mediated inhibition of the medullary dorsal horn neurons, and thus theoretically has potential to suppress opioid-induced pruritus. OBJECTIVES: This prospective double-blinded randomized trial aimed at comparing the effects of propofol, midazolam, and a combination of the two on the prevention of pruritus induced by intrathecal sufentanil. METHODS: Eighty-four patients undergoing spinal anesthesia with 3 mL hyperbaric bupivacaine 0.5% and 5 μg sufentanil (1 mL) were randomly allocated to one of the three study groups: Group 1, who were administered 20 mg intravenous (IV) propofol bolus, then 50 μg/kg/min IV infusion; Group 2, who were administered 0.03 mg/kg IV midazolam bolus, then 0.02 mg/kg/h IV infusion; and Group 3, who were administered 10 mg IV propofol and 0.015 mg/kg IV midazolam bolus, then 25 μg/kg/min propofol and 0.01 mg/kg/h midazolam IV infusion. The incidence rates and severity of pruritus were assessed intraoperatively and postoperatively for 24 hours. RESULTS: The Ramsay Sedation Score was highest for the propofol group throughout the duration of the anesthetic process. Overall, 17 patients in the propofol group (60.7%), eight patients in the midazolam group (28.6%), and nine patients in the propofol-midazolam group (32.1%) developed pruritus (P = 0.027). Intraoperative pruritus was observed in seven patients in the propofol group (25%), two patients in the midazolam group (7.1%), and five patients in the midazolam-propofol group (17.9%) (P = 0.196). Postoperative pruritus developed in 12 patients in the propofol group (42.9%), six patients in the midazolam group (21.4%), and four patients in the midazolam-propofol group (14.3%) (P = 0.041). There was no significant difference between the groups with respect to the severity of pruritus (P > 0.05). CONCLUSIONS: This study showed that in comparison with propofol, the administration of 0.03 mg/kg IV midazolam bolus followed by 0.02 mg/kg/h could be more effective in the prevention of intrathecal sufentanil-induced pruritus without increasing sedation and other side effects. Kowsar 2016-08-27 /pmc/articles/PMC5696882/ /pubmed/29181332 http://dx.doi.org/10.5812/aapm.37535 Text en Copyright © 2017, Iranian Society of Regional Anesthesia and Pain Medicine (ISRAPM) http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Makarem, Jalil
Mireskandari, Seyed Mohammad
Jafarzadeh, Afshin
Rahbar Nikoukar, Laya
Aghaii, Sara
Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial
title Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial
title_full Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial
title_fullStr Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial
title_full_unstemmed Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial
title_short Intravenous Midazolam as More Effective Than Propofol for Preventing Pruritus After Intrathecal Sufentanil in Surgical Patients: A Randomized Blinded Trial
title_sort intravenous midazolam as more effective than propofol for preventing pruritus after intrathecal sufentanil in surgical patients: a randomized blinded trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696882/
https://www.ncbi.nlm.nih.gov/pubmed/29181332
http://dx.doi.org/10.5812/aapm.37535
work_keys_str_mv AT makaremjalil intravenousmidazolamasmoreeffectivethanpropofolforpreventingpruritusafterintrathecalsufentanilinsurgicalpatientsarandomizedblindedtrial
AT mireskandariseyedmohammad intravenousmidazolamasmoreeffectivethanpropofolforpreventingpruritusafterintrathecalsufentanilinsurgicalpatientsarandomizedblindedtrial
AT jafarzadehafshin intravenousmidazolamasmoreeffectivethanpropofolforpreventingpruritusafterintrathecalsufentanilinsurgicalpatientsarandomizedblindedtrial
AT rahbarnikoukarlaya intravenousmidazolamasmoreeffectivethanpropofolforpreventingpruritusafterintrathecalsufentanilinsurgicalpatientsarandomizedblindedtrial
AT aghaiisara intravenousmidazolamasmoreeffectivethanpropofolforpreventingpruritusafterintrathecalsufentanilinsurgicalpatientsarandomizedblindedtrial